[HTML][HTML] Direct oral anticoagulation and severe obesity–One size fits all?
Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …
Meta-analysis comparing direct oral anticoagulants versus warfarin in morbidly obese patients with atrial fibrillation
K Kido, M Shimizu, T Shiga, M Hashiguchi - The American journal of …, 2020 - Elsevier
Highlights•Direct oral anticoagulants did not increase stroke or systemic embolism event
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …
Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation
Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
Safety and efficacy of direct oral anticoagulants in comparison to warfarin in obese patients with atrial fibrillation: A systematic review and meta‐analysis
A Adelkhanova, PR Oli, DB Shrestha… - Health Science …, 2024 - Wiley Online Library
Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …
Comparative effectiveness and safety of doac versus warfarin among obese with atrial fibrillation
Background: Limited real-world data exist on the comparative effectiveness and safety of
direct oral anticoagulants (DOACs) compared to warfarin in obese patients with atrial …
direct oral anticoagulants (DOACs) compared to warfarin in obese patients with atrial …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanic, I Jurin, H Jurin, T Lucijanic… - International journal of …, 2020 - Elsevier
Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …
about their efficacy in a population of obese/overweight patients. Patients and methods We …
Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis
Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …
Use of direct oral anticoagulants in morbidly obese patients
K Kido, JC Lee, T Hellwig… - … : The Journal of Human …, 2020 - Wiley Online Library
In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …
Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation
K Kido, S Ngorsuraches - Annals of Pharmacotherapy, 2019 - journals.sagepub.com
Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …
Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An …
P Karakasis, N Ktenopoulos, K Pamporis… - Journal of Clinical …, 2024 - mdpi.com
Background: Real-world data show limited utilization of direct oral anticoagulants (DOACs)
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …